Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Cancer Res. 2014 May 8;74(15):4042–4052. doi: 10.1158/0008-5472.CAN-13-2685

Figure 2.

Figure 2

Anti-tumor responses from TEGVAX were found in multiple tumor models. A. TEGVAX induced anti-tumor response in palpable CT26 colon carcinoma and palpable SCCFVII tongue carcinoma models compared to controls (**P<0.01). CT26-GM and SCCFVII-GM vaccine was prepared as described previously (43, 44). C3H/HeOUJ mice treated with TEGVAX also demonstrated anti-tumor response (** P<0.01). B. Palpable B16 bearing mice were treated with multiple injections of vaccines and TLR agonists on day7, day14 and day21 (arrow) (** P<0.01).